Email Updates

Search form

You are here

HIV Seroconversion in the Era of Pharmacologic Prevention: A Case–Control Study at a San Francisco STD Clinic

Include in
Published Research

MSM who ever used PrEP demonstrated equal or higher sexual risk compared with those using neither PrEP nor PEP but had 76 percent lower odds of HIV seroconversion. MSM who used PEP but never PrEP were no less likely to seroconvert than those using neither. MSM should be offered PrEP. PEP users with ongoing risk of HIV infection should be connected to PrEP after PEP.

October 1, 2019